Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Mi Jie Park
Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, With Dapagliflozin and Ipragliflozin
Pharmaceutics
Pharmaceutical Science
Related publications
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Empagliflozin, a Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor, in Healthy Japanese Subjects
Drug Metabolism and Pharmacokinetics
Pharmacology
Pharmaceutical Science
The Sodium–Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model
Diabetes
Internal Medicine
Endocrinology
Metabolism
Diabetes
Protective Effects of Ipragliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, on a Non-Alcoholic Steatohepatitis Mouse Model
Yonago Acta Medica
Medicine
Clinical Risk Factors Predicting Genital Fungal Infections With Sodium–glucose Cotransporter 2 Inhibitor Treatment: The ABCD Nationwide Dapagliflozin Audit
Primary Care Diabetes
Internal Medicine
Nutrition
Endocrinology
Dietetics
Metabolism
Diabetes
Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor Related Diabetic Ketoacidosis
European Scientific Journal ESJ
In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
Biological and Pharmaceutical Bulletin
Medicine
Pharmacology
Pharmaceutical Science
Pharmacokinetics and Pharmacodynamics of a Novel Acetylcholinesterase Inhibitor, DMNG-3
Acta Neurobiologiae Experimentalis
Medicine
Neuroscience
Increased Grip Strength With Sodium-Glucose Cotransporter 2
Journal of Diabetes
Endocrinology
Metabolism
Diabetes
Ertugliflozin: A Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitor for Glycemic Control in Type 2 Diabetes
Therapeutics and Clinical Risk Management
